Editors:
- Describes both established signal transduction inhibitors as well as emerging molecularly-guided immunotherapies
- Places exciting developments in basic biological understanding into a practical clinical context
- The first book on melanoma devoted entirely to targeted therapeutics
- Includes the most up-to-date data from current clinical Phase I-III trials
- Written by high-profile authors representing the world’s leaders in their field
- Includes supplementary material: sn.pub/extras
Part of the book series: Current Clinical Oncology (CCO)
Buy it now
Buying options
Tax calculation will be finalised at checkout
Other ways to access
This is a preview of subscription content, log in via an institution to check for access.
Table of contents (18 chapters)
-
Front Matter
-
Advances in Melanoma Biology
-
Front Matter
-
-
Signaling Molecules as Molecular Targets
-
Front Matter
-
-
Rational Immunotherapy Approaches in Melanoma
-
Front Matter
-
About this book
Melanoma is an increasingly important public health problem. Although the cause of most malignant melanomas – over-exposure to ultraviolet light – is well known, effective treatment has remained challenging.
The past several years have been marked by extraordinary developments in melanoma treatment in the arena of targeted therapeutics. This book describes these ground-breaking discoveries and their implications for clinical use. As melanoma biology is increasingly understood, so the development of targeted therapies for this disease is spurred ahead. This book covers both established signal transduction inhibitors and the fascinating emerging realm of molecularly-guided immunotherapies.
This benchmark book provides the most up-to-date information on the new breed of melanoma therapies. Composed of the works of major researchers and clinicians, this book offers new insights, novel approaches, and promising data for effective treatment planning. Illuminating the latest advances in the field, it is a solid resource for clinical oncologists, translational scientists, and basic cancer researchers.
Reviews
From the reviews:
“This book is a multiauthored edition, with contributors and editors who are experts in their fields regarding new therapeutic approaches for melanoma. … It is a highly technical volume and is directed toward true melanoma mavins, both clinical and laboratory research based, who continue to work at the translational interface. … I recommend this to all those clinical, translational, and laboratory investigators committed to moving the field forward in the development of treatment for melanoma.” (Janice P. Dutcher, Medical Oncology, Vol. 30, 2013)Editors and Affiliations
-
, Pathology, University of Chicago, Chicago, USA
Thomas F. Gajewski
-
, Melanoma Disease Center, Dana-Farber Cancer Institute, Boston, USA
F. Stephen Hodi
Bibliographic Information
Book Title: Targeted Therapeutics in Melanoma
Editors: Thomas F. Gajewski, F. Stephen Hodi
Series Title: Current Clinical Oncology
DOI: https://doi.org/10.1007/978-1-61779-407-0
Publisher: Humana Totowa, NJ
eBook Packages: Medicine, Medicine (R0)
Copyright Information: Springer Science+Business Media, LLC 2012
Hardcover ISBN: 978-1-61779-406-3Published: 14 December 2011
Softcover ISBN: 978-1-62703-876-8Published: 03 March 2014
eBook ISBN: 978-1-61779-407-0Published: 15 December 2011
Series ISSN: 2364-1134
Series E-ISSN: 2364-1142
Edition Number: 1
Number of Pages: XIV, 378
Topics: Oncology, Cancer Research